Anzeige
Mehr »
Login
Mittwoch, 06.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus“ in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Actusnews Wire
593 Leser
Artikel bewerten:
(2)

SQLI: 2019 ANNUAL RESULTS // SOLID EARNINGS GROWTH

Press release

24 March 2020

European digital services group SQLI presents its full-year results as approved at the Board of Directors meeting on 17 March 2020 chaired by Philippe Donche-Gay. The statutory auditors have conducted their review of the full-year financial statements. The certification report will be issued upon completion of the requisite procedures for publication of the 2019 Universal Registration Document.

€m - IFRS20182019Change
TURNOVER232.0238.7+3%
EBITDA[1]14.115.1+7%
6.1%6.3%+0.2 pp
RECURRING EBIT12.213.2+8%
5.3%5.5%+0.2 pp
EBIT8.09.7+21%
3.4%4.1%+0.7 pp
NET INCOME3.14.7+52%


EBIT UP 21% AND NET INCOME UP 52%

At €238.7m,[2], yearly sales rose 2.9% (up 2.5% at constant exchange rates), due to double-digit growth in Commerce & Experience (up 11.3%). The European digital agency business now accounts for 43% of consolidated turnover versus 40% in 2018. Boosted by this shift in the business mix, combined with the initial benefits generated by the focus on streamlining organisation and processes in the French digital services business, Digital & Technology, EBITDA rose 7% to €15.1m and recurring EBIT rose 8% to €13.2m. The recurring EBIT margin came to 5.5% of turnover, up 0.2 percentage points year-on-year.

Meanwhile, in line with its roadmap, SQLI significantly reduced non-recurring result[3], down 17% in 2019 and halved in 2 years to €3.5m. EBIT came to €9.7m, up 21% year-on-year. Measures implemented in 2019 to streamline operations are expected to generate recurring savings of more than €1m on a full-year basis.

After factoring in net cost of debt, down 17% year-on-year to €2.2m, and tax expense (€3.3m versus €2.0m in 2018), net income rose 52% to €4.7m.

HEALTHY BALANCE SHEET

At 31 December 2019, SQLI's cash balance stood at €20.1m, underpinned by an unused factoring reserve. Net debt excluding IFRS 16 lease liabilities[4] totalled €14.5m and amounted to 0.96 times EBITDA and 15% of shareholders' equity (€94.7m).

EXPANSION OF COMMERCE & EXPERIENCE IN THE UK

The Group's determination to play a unifying role in the European digital agency market, in accordance with the ONE FORCE 2022 strategic plan, is reflected in its acquisition, early March 2020, of Redbox Digital, an agency based in the UK and Dubai specialising in e-commerce and employing 80 people.

This new, instantly accretive acquisition enables SQLI to enhance its portfolio of key accounts (including AXA Insurance, Nahdi Medical, Nespresso, Fortnum & Mason and Universal Music Group) and thus become one of the 10 "Global Elite Partners" of Adobe/Magento, the world's leading e-commerce platform.

In 2019 Redbox posted sales of €7.3m, growth of around 10% and a double-digit recurring EBIT margin. SQLI acquired 60% of Redbox's share capital and has an option on the balance held by the management team, which remains fully committed to the Group's business strategy and vision.

TRENDS AND OUTLOOK

FY 2020 is the first year of the ONE FORCE 2022 plan which, backed by the growth of its two core divisions and the ramp-up of resources in its Digital Services Centres, should enable the Group to embark on a strong upward growth trajectory. SQLI thus forecasts consolidated turnover of over €280m by 2022 and recurring EBIT in excess of €22m by the same year.

The Group remains highly vigilant in the face of developments in the health crisis and its economic consequences. In the short term, a business continuity plan has been successfully implemented, including widespread use of teleworking in order to protect employees and ensure they can continue to perform their assignments. However, containment measures are starting to have a noticeable impact on business volumes, particularly in France. The Group has therefore implemented daily monitoring of its employment rate and an action plan, particularly in response to the exceptional measures implemented by the public authorities, to safeguard its cash.

Given daily developments in the situation, SQLI plans to provide an initial review of the impact of the COVID-19 epidemic on its business when it publishes its Q1 2020 turnover. At this stage, in view of the significant slowdown in business, the Group confirms its medium-term ambitions but is not providing any quantified guidance for the 2020 financial year.

SQLI will publish Q1 2020 turnover on 28 April 2020 after close of trading.

Receive SQLI financial news free of charge by email by signing on at: www.actusnews.com

About SQLI: Founded in 1990, SQLI is an international digital services group, combining the best technologies and methods to create user focused applications and services and e-Commerce solutions that enhance the customer experience.

Its unique positioning as a trade, technology and skill transformation specialist, combined with the production capacity of its digital services centres, enable SQLI Group to help European key accounts increase their sales, reputation and internal performance over the long term.

SQLI's 2,400 employees are spread over 32 agencies in 13 countries: France, Switzerland, Luxembourg, Belgium, the United Kingdom, Ireland, Germany, Sweden, the Netherlands, Denmark, Spain, South Africa and Morocco. SQLI posted turnover of €232 million in 2018 and has been listed on Euronext Paris (SQI) since July 21, 2000.

https://www.sqli.com

Follow SQLI on Linkedin
Follow SQLI on Facebook and Twitter

Investor Relations

Olivier Stephan - +33 (0)1 85 64 20 20 - ostephan@sqli.com

Jerôme Fabreguettes-Leib - +33 (0)1 53 67 36 78 - jfl@actus.fr

Financial Press Relations

Nicolas Bouchez - +33 (0)1 53 67 36 74 - nbouchez@actus.fr


[1]EBITDA = Recurring EBIT + net depreciation, amortisation and provision charges (excl. IFRS 16)

[2] €239.2m pre-audit estimate announced on 6 February 2020

[3] Non-recurring operating income and expenses

[4] Lease liabilities of €29.5 million maturing in more than one year and €7.8m maturing within one year

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yWdslZZnYmfJxnKdapibaZWWZphmmGOcZ2PHk2dua8qUmW5jx5pqbJvHZm9jm2dt
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-62627-sqli_cp_ra_2019_uk_vdef.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2020 Actusnews Wire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.